TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05361174: A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Canc

Sponsor: Iovance Biotherapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 53 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,727,880

Rescue Site Savings

+$1,138,830

Unlock Full NCT05361174 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05361174 Rescue Dossier →